← All trials
NCT04676659
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2018
- Primary completion
- May 30, 2020
- Completion date
- Jul 10, 2020
- First posted
- Dec 21, 2020
- Last posted
- Dec 21, 2020
- Enrollment
- 240
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Zhengzhou UniversityCollaborator
- Hebei UniversityCollaborator
- Jilin UniversityCollaborator
- Jinan UniversityCollaborator
- Sichuan UniversityCollaborator
- Capital Medical UniversityReponsible party - principal investigator
- Fudan UniversityCollaborator
- Qingdao UniversityCollaborator
- Baotou Medical UniversityCollaborator
- Linyi People's HospitalCollaborator
- Guangzhou Recomgen Biotech Co., Ltd.Collaborator
- Inner Mongolia Baogang HospitalCollaborator
- Capital Medical UniversityStudy director
- The First Hospital of Qiqihar CityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.